These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
244 related items for PubMed ID: 19999176
21. Comments on ''Geranylgeraniol--a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw" by Ziebart T et al. (2011). Marcuzzi A, Zanin V, Crovella S, Pontillo A. Oral Oncol; 2011 May; 47(5):436-7; author reply 438. PubMed ID: 21411362 [No Abstract] [Full Text] [Related]
22. [Osteonecrosis of the jaw]. Drozdzowska B. Endokrynol Pol; 2011 May; 62 Suppl 3():4-9. PubMed ID: 22161980 [Abstract] [Full Text] [Related]
23. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Van Poznak C, Estilo C. Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349 [Abstract] [Full Text] [Related]
27. Complication related to bisphosphonate therapy: osteonecrosis of the jaw. Lee J. J Infus Nurs; 2009 Aug; 32(6):330-5. PubMed ID: 19918142 [Abstract] [Full Text] [Related]
29. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Pazianas M, Blumentals WA, Miller PD. Osteoporos Int; 2008 Jun; 19(6):773-9. PubMed ID: 17999023 [Abstract] [Full Text] [Related]
30. Re: Christian Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72. Kyrgidis A, Teleioudis Z, Vahtsevanos K. Eur Urol; 2009 Apr; 55(4):e72-3; author reply e74-5. PubMed ID: 18718705 [No Abstract] [Full Text] [Related]
31. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ruggiero SL. Ann N Y Acad Sci; 2011 Feb; 1218():38-46. PubMed ID: 20946580 [Abstract] [Full Text] [Related]
32. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Reid IR, Bolland MJ, Grey AB. Bone; 2007 Sep; 41(3):318-20. PubMed ID: 17572168 [Abstract] [Full Text] [Related]
33. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K. Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032 [Abstract] [Full Text] [Related]
35. Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72. Berruti A, Ortega C, Fusco V. Eur Urol; 2009 Mar; 55(3):e61-2. PubMed ID: 18945537 [No Abstract] [Full Text] [Related]
36. Osteonecrosis of the jaws: maxillofacial recommendations for bisphosphonate prescribers. Landis BN, Dojcinovic I, Richter M, Hugentobler M. J Intern Med; 2007 Jan; 261(1):101-2. PubMed ID: 17222173 [No Abstract] [Full Text] [Related]
38. Bisphosphonate-related osteonecrosis of the jaws an old disease with a new drug? Carlson ER. Cranio; 2010 Jan; 28(1):1-2. PubMed ID: 20158003 [No Abstract] [Full Text] [Related]
39. Osteonecrosis: what does it mean? One condition partly caused by bisphosphonates--or another one, preferably treated with them? Aspenberg P. Acta Orthop; 2006 Oct; 77(5):693-4. PubMed ID: 17068696 [No Abstract] [Full Text] [Related]
40. Closing in on the Puzzle of ONJ. Glick M. J Am Dent Assoc; 2008 Jan; 139(1):12, 14-5. PubMed ID: 18167371 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]